$Johnson & Johnson(JNJ.US) buyers spotted stepping into the $280C for 10/16, loading up with over $1.10M in premium. 👀
Johnson & Johnson
JNJ----
Share your thoughts
Write something you'd like to share with our community...
- S
Johnson and Johnson US stock is still good US stock that is rising and having good divident. It has earn me about 12% profit thus far. i had bought the share at the price of USD 225.95 and now rise to the price of USD 253.89. Feel free to share your valuable insights and feedback about the stocks.
- S
This is my US defensive growth and dividvents stocks that i am holding. Feel free to comment on my holdings.
- L
Inspired by Warren Buffet’s portfolio, I’ve decided to build a position in JNJ, another one of his “dividend kings”. Just like KO, so far its not looking too good though :/
Trade Showcase: Trade, Show & Earn Rewards! - S
This is my humble U.S. stock holdings, mainly made up of defensive income stocks. I know my portfolio is still very much a newbie’s collection, but I’m learning as I go. I’d really appreciate any advice, comments, or suggestions on how I can improve my holdings and build a stronger portfolio over time.
Trade Showcase: Trade, Show & Earn Rewards! - 月
The S&P 500 index hits a new high of 6978! Up 44% this year, aiming for 7500-8000 in 2026, the AI bull market continues!
The Nasdaq 7 giants led the gains, with the S&P 500 surging from 4835 to 6978 (+44%) this year, with 2.7 billion in turnover confirming bullish dominance, easily breaking the 50-day moving average of 6840! JPMorgan's 2026 outlook at 7500: Fed rate cuts + AI capital expenditures support earnings growth of 13-15%, optimistic for 8000: If additional easing occurs, the S&P could rise another 15%, led by Amazon, NVIDIA, and Google. Conservative 7100: BofA slightly pessimistic, 4% gain, wary of AI bubble + consumer contraction. Investment strategy: Index ETFs like SPY and VOO for dollar-cost averaging, diversifying risks to capitalize on S&P dividends...
- B
(RXRX.US) vs. XtalPi (2228.HK) by Qwen app
$Recursion Pharmaceuticals(RXRX.US) Recursion Pharmaceuticals (RXRX.US) vs. XtalPi (2228.HK)$XTALPI(02228.HK) In-depth competitive benchmarking analysis: Comparison of technological pathways, business strategies, and investment value between the two leading AI-driven drug discovery platforms globally. I. Core Positioning & Strategic Vision Comparison DimensionRecursion Pharmaceuticals (RXRX) Xta...
